ModernMedicine Resource Center More Topics

Bladder Cancer Resource Center

Cisplatin nanoparticles appear efficacious for treating NMIBCThe use of intravesical cisplatin nanoparticles reduces cancer cell proliferation while limiting drug absorption beyond the bladder barrier, according to early findings.
Bladder Ca subtypes ID’d, may yield personalized therapiesResearchers from The Cancer Genome Atlas Research Network have outlined five distinct expression subtypes of muscle-invasive bladder cancer, each of which may be targetable by different treatments.
Two-drug therapy for advanced UC shows superior PFSAdding ramucirumab (CYRAMZA) to standard docetaxel (Taxotere) improved progression-free survival compared with docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.
Better models needed for predicting bladder Ca recurrenceCurrent NCCN guidelines are comparable to European models for predicting nonmuscle-invasive bladder cancer recurrence and progression. But better models are needed, according to a recent study.
Investigational BCG-refractory NMIBC Tx shows promise“rAd-IFNα gene therapy is a breakthrough opportunity for effective local management of BCG-unresponsive NMIBC,” says researcher Colin P. N. Dinney, MD.
Bladder Ca photothermal treatment yields encouraging resultsPhotothermal treatment with epidermal growth factor receptor-directed gold nanorods results in considerable antineoplastic activity in an early study of bladder cancer.
Smoking linked to tumor heterogeneity for bladder CaResearchers from Wake Forest Baptist Comprehensive Cancer Center have made novel discoveries about the genomic signatures of cancers—including bladder cancer—in smokers and African-American patients.
Genomic research may explain resistance to immunotherapyNew research characterizing the molecular mechanisms regulating immune cell infiltration into the luminal subtype of muscle-invasive bladder cancer may explain resistance to treatment with immune checkpoint blockade and suggest a target for improving therapeutic response.
QoL better with bladder Ca immunotherapy vs. chemoPatients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
Robotic vs. open cystectomy: How PFS, OS compareEvaluation of upper tract surveillance for high-grade, nonmuscle-invasive bladder cancer and evidence suggesting that androgen receptor activity may be related to recurrence and treatment of bladder cancer were among the take-home messages in this area from AUA 2017.